Get started
Author

Krishna Mohan Vadrevu

Observed names: Krishna Mohan Vadrevu, Krishna M. Vadrevu
Observed institution: Bharat Biotech (India)
ORCID: 0009-0002-2477-4580
Observed ORCID: 0009-0002-2477-4580
OpenAlex ID: A5073308961
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
2021 · Raches Ella, Krishna Mohan Vadrevu, et al. · The Lancet Infectious Diseases · 427
PDF
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
2021 · Raches Ella, Siddarth Reddy, et al. · The Lancet · 387
PDF
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
2021 · Raches Ella, Siddharth Reddy, et al. · The Lancet Infectious Diseases · 382
PDF
Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2
2021 · Gajanan N Sapkal, Pragya D Yadav, et al. · Journal of Travel Medicine · 121
PDF
Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
2021 · Pragya D. Yadav, Raches Ella, et al. · Nature Communications · 106
PDF
Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)
2023 · Chandramani Singh, Savita Verma, et al. · npj Vaccines · 99
PDF
Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
2021 · Brunda Ganneru, Harsh Jogdand, et al. · iScience · 94
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
2021 · Sreelekshmy Mohandas, Pragya D. Yadav, et al. · iScience · 71
Persisting antibody responses to Vi polysaccharide–tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination
2021 · Krishna Mohan Vadrevu, Dugyala Raju, et al. · Vaccine · 42
PDF
Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
2022 · Raju Sunagar, Sai D. Prasad, et al. · Frontiers in Immunology · 40
PDF
Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants
2022 · Krishna Mohan Vadrevu, Brunda Ganneru, et al. · Scientific Reports · 40
PDF
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study
2022 · Krishna Mohan Vadrevu, Siddharth Reddy, et al. · The Lancet Infectious Diseases · 38
PDF
Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152
2020 · Brunda Ganneru, Harsh Jogdand, et al. · SSRN Electronic Journal · 30
Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine
2019 · Krishna Mohan Vadrevu, Venugopal Potula, et al. · The Journal of Infectious Diseases · 27
PDF
Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern
2022 · Gururaj Rao Deshpande, Pragya D Yadav, et al. · Journal of Travel Medicine · 24
A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India
2018 · Raches Ella, Radhika Bobba, et al. · Human Vaccines & Immunotherapeutics · 21
PDF
A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants
2019 · Raches Ella, Sudhir Babji, et al. · Vaccine · 19
PDF
Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model
2022 · Pragya D. Yadav, Sreelekshmy Mohandas, et al. · iScience · 13
Effect of heterologous intranasal iNCOVACC® vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial
2025 · Venkateshwar Rao Akula, Amit Suresh Bhate, et al. · Communications Medicine · 11
PDF
Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8–9 months-old Indian children
2022 · Krishna Mohan Vadrevu, Raju Dugyala, et al. · Human Vaccines & Immunotherapeutics · 9
Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152: A Phase 1, Double-Blind, Randomised Control Trial
2020 · Raches Ella, Krishna Mohan Vadrevu, et al. · SSRN Electronic Journal · 8
Immunogenicity and Tolerability of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-2 Vaccine, Compared with Intramuscular Covaxin® in Healthy Adults: A Randomised, Open-Label, Phase 3 Clinical Trial
2023 · Chandramani Singh, Savita Verma, et al. · SSRN Electronic Journal · 7
Comparative immune response of Typbar TCV® (typhoid conjugate vaccine) in extremes of age: An Indian experience
2025 · Krishna Mohan Vadrevu, Siddharth Reddy Chiteti, et al. · Human Vaccines & Immunotherapeutics · 6
PDF
Phase III randomized clinical studies to evaluate the immunogenicity, lot-to-lot consistency, and safety of ROTAVAC® liquid formulations (ROTAVAC 5C & 5D) and non-inferiority comparisons with licensed ROTAVAC® (frozen formulation) in healthy infants
2023 · Krishna Kumari P, Siddharth Reddy Chiteti, et al. · Human Vaccines & Immunotherapeutics · 5
PDF
A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™
2025 · Krishna Mohan Vadrevu, Abhishek Chavan, et al. · Vaccine · 4
Works count: 28
Citation count: 2,027
H-index: 17
I10-index: 19
Year
Topic
Type